eXoZymes专注于NCT计划和大麻素管道的内部开发,旨在2027年推出. eXoZymes focuses on internal development for NCT program and cannabinoid pipeline, aiming for a 2027 launch.

报告称,exoZymes (EXOZ) 在NCT计划和大麻素管道中专注于内部开发而不是合作伙伴关系. eXoZymes (EXOZ) reported focusing on internal development over partnerships for its NCT program and cannabinoid pipeline. 该公司的无细胞平台使其可扩展,纯生产成为可能,首款产品NCTx将于2027年推出营养药. The company's cell-free platform enables scalable, pure production, with its first product NCTx targeting a 2027 nutraceutical launch. 面对现金短缺,eXoZymes计划进行新一轮融资以支持运营和商业化工作. Facing cash shortages, eXoZymes plans a new financing round to support operations and commercialization efforts.